Histopathology and clinical correlates of end-stage hepatitis B cirrhosis: A possible mechanism to explain the response to antiviral therapy

Liver Transplantation

Volumn 11, Issue 1, 2005, Pages 82-88

  Sigal, Samuel H ^a   Ala, Aftab ^b   Ivanov, Katya ^c   Hossain, Sabera ^c   Bodian, Carol ^c   Schiano, Thomas D ^b   Min, Albert D ^d   Bodenheimer Jr , Henry C ^d   Thung, Swan N ^c  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b Recanati/Miller Transplantation Institute   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; HEPATITIS B CORE ANTIGEN;

ADULT; AGE; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; ASIAN; CHEMICAL PARAMETERS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE SEVERITY; DNA DETERMINATION; DRUG RESPONSE; ETHNOLOGY; EXPLANT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER CIRRHOSIS; LIVER FAILURE; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MALE; MICROBIOLOGICAL PARAMETERS; PRIORITY JOURNAL; SERODIAGNOSIS;

ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TRANSAMINASES;

EID: 12344253963     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20328     Document Type: Article

References (41)

1. Agalar C, Diri C, Usubutun S, Agalar F, Turkyilmax R. The role of HBV DNA and liver histopathology in HBsAg carriers. Hepatogastroenterology 1997;44:1196-1199.
2. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991;32:294-298.
3. Paz MO, Brenes F, Karayiannis P, Jowett TP, Scheuer PJ, Thomas HC. Chronic hepatitis B virus infection, viral replication and patterns of inflammatory activity: serological, clinical and histological correlations. J Hepatol 1986:3:371-377.
4. ter Borg F, ten Kate FJ, Cuypers HT, Leentvaar-Kuijpers A, Oosting J, Wertheium-van Dillen PM, et al. Relation between laboratory test results and histological hepatitis activity in individuals positive for hepatitis B surface antigen and antibodies to hepatitis Be antigen. Lancet 1998;351:1914-1918.
5. Zavaglia C, Mondazzi L, Maggi G, Iamoni G, Gelosa F, Bellati G, et al. Are alanine aminotransferase, hepatitis B virus DNA or IgM antibody to hepatitis B core antigen serum levels predictors of histological grading in chronic hepatitis B? Liver 1997;17:83-87.
6. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic hepatitis type B hepatitis. Ann Intern Med 1981;94:744-748.
7. Realdi G, Alberti A, Rugge M, Bortolotti F, Rigoli AM, Tremolada F, Ruol A. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 1980;79:195-199.
8. Chu CM, Karayiannis P, Fowler MJ, Monjardino J, Liaw YF, Thomas HC. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology 1985;5:431-434.
9. Andres LL, Sawhney VK, Scullard GH, Smith JL, Merigan TC, Robinson WS, Gregory PB. Dane particle DNA polymerase and HBeAg: impact on clinical, laboratory, and histologic findings in hepatitis B-associated chronic liver disease. Hepatology 1981;1: 583-585.
10. Craxi A, Weller IV, Bassendine MF, Fowler MJ, Monjardino J, Thomas HC, Sherlock S. Relationship between HBV-specific DNA polymerase and HBe antigen/antibody system in chronic HBV infection: factors determining selection of patients and outcome of antiviral therapy. Gut 1983;24:143-147.
11. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004;350:1118-1129.
12. Mangia A, Chung Y-H, Hoofnagle JH, Birkenmeyer L, Mushahwar I, DiBisceglie AM. Pathogenesis of chronic liver disease in patients with chronic hepatitis B virus infection without serum HBeAg. Dig Dis Sci 1996;41:2447-2452.
13. Niederau C, Heintges T, Lange S, Goldman G, Niederau CM, Mohr L, Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427.
14. Fattovich G, Rugge M, Brollo L, Pontisso P, Noventa F, Guido M, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis B. Hepatology 1986;6:167-172.
15. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, Liaw YF. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002;35:1522-1527.
16. Roberts SK, Therneau TM, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996;110:848-857.
17. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White R Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193-199.
18. Deland FH, North WA. Relationship between liver size and body size. Radiology 1968;91:1195.
19. Batts KP, Ludwig J. Chronic hepatitis, an update on terminology and reporting. Am J Surg Pathol 1995;19:1409-1417.
20. Thung SN, Gerber MA, Sarno E, Popper H. Distribution of 5 antigens in hepatocellular carcinoma. Lab Invest 1979;41:101-105.
21. Hadziyannis SJ, Lieberman HM, Karvountzis GG, Shafritz DA. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg vs anti-HBe positive carriers of hepatitis B virus. Hepatology 1983;3:656-662.
22. Trepo CB, Magnius LO, Schaefer RA, Prince AM. Detection of e antigen and antibody: correlations with hepatitis B surface and hepatitis B core antigens, liver disease, and outcome in hepatitis B infections. Gastroenterology 1976;71:804-808.
23. Bonino F, Hoyer B, Nelson J, Engle R, Verme G, Gerin J. Hepatitis B virus DNA in the sera of HBsAg carriers: a marker of active hepatitis B virus replication in the liver. Hepatology 1981; 1:386-391.
24. Dragosics B, Ferenci P, Hitchman E, Denk H. Long-term follow-up study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histologic evaluation of 242 cases. Hepatology 1987;7:302-306.
25. Bonino F, Rosina F, Rizzetto M, Rizzi R, Chiaberge E, Tardanico R, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986;90:1268-1273.
26. Chon CY, Han KH, Lee KS, Moon YM, Kang JK, Park IS, et al. Peritoneoscopic liver biopsy findings in asymptomatic chronic HBsAg carriers with normal liver function tests and no hepatomegaly. Yonsei Med J 1996;37:295-301.
27. de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninn E, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993;118:191-194.
28. Karayiannis P, Fowler MJF, Lok AS, Greenfield C, Monjardino J, Thomas HC. Detection of serum HBV-DNA by molecular hybridization: correlation with HBeAg/anti-HBe status, racial origin, liver histology and hepatocellular carcinoma. J Hepatol 1985;1:99-106.
29. Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994;21:656-656.
30. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988;8:493-496.
31. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90.
32. Villeneuve J-P, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-210.
33. Wiegand J, Thischendorf JJ, Nashan B, Klempnauer J, Flemming P, Niemann P, et al. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated. Z Gastroenterol 2004;42:15-18.
34. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000;33:301-307.
35. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 2001;34:411-416.
36. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir diovoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348: 808-816.
37. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
38. Autschbach F, Meuer SC, Moebius U, Manns M, Hess G, Meyer zum Buschenfelde KH, et al. Hepatocellular expression of lymphocyte function-associated antigen 3 in chronic hepatitis. Hepatology 1991;14:223-230.
39. Malekzadeh R, Mohamadnejad M, Rakhshani N, Nasseri-Moghaddam S, Merat S, Tavangar SM, et al. Reversibility of cirrhosis in chronic hepatitis B. Clin Gastroenterol Hepatol 2004;2:344-347.
40. Keeffe EB, Dieterich DT, Han S-H et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004;2:87-106.
41. Han LH, Sun WS, Ma CH, Zhang LN, Liu SX, Zhang Q, et al. Detection of soluble TRAIL in HBV infected patients and its clinical implications. World J Gastroenterol 2002;8:1077-1080.